Lehmann Christian, Meissner Konrad, Knöck Andreas, Diedrich Stephan, Pavlovic Dragan, Gründling Matthias, Usichenko Taras, Wendt Michael, Birnbaum Jürgen
Klinik und Poliklinik für Anästhesiologie und Intensivmedizin, Ernst Moritz Arndt University, Greifswald, Germany.
Crit Care. 2006;10(6):R157. doi: 10.1186/cc5093.
Successful treatment of severe sepsis and septic shock remains a major challenge in critical care medicine. The recently introduced recombinant human activated protein C (APC) remarkably improved the outcome of septic patients. The influence of APC on intestinal circulation is still poorly understood. Therefore, the present study aimed to investigate the effects of APC on intestinal microcirculation during experimental endotoxaemia in rats by using intravital microscopy.
A total of 44 male Lewis rats were randomly assigned to receive intravenous injections of 15 mg/kg lipopolysaccharide alone (LPS) (n = 11) or LPS followed by subsequent injection of 2 mg/kg recombinant human APC (LPS + APC) (n = 11), whereas control animals received either APC (n = 11) or saline (n = 11). Animals underwent observations of functional capillary density and leucocyte adherence on venular endothelium in the microcirculation of the intestinal wall by means of intravital fluorescence microscopy. Indicators of macrocirculation as well as plasma levels of tumour necrosis factor-alpha, interleukin (IL)-1beta, IL-6, and IL-10 were measured.
Although APC administration of both LPS-treated and control rats did not change macrocirculation or release of inflammatory cytokines, it increased mucosal and muscular functional capillary density (p < 0.001 and p < 0.05, respectively) and reduced the number of firmly adhering leucocytes in intestinal submucosal V1 and V3 venules (p < 0.01) in LPS + APC-treated compared with LPS-treated animals, which did not receive APC. No remarkable differences that could be attributed to APC treatment were observed between the two control groups.
APC administration during experimental endotoxaemia improved intestinal microcirculation by protecting functional capillary density as a measure of microvascular perfusion and exerted anti-inflammatory effects by reducing leucocyte adherence to the endothelium in submucosal venules. Therefore, beneficial effects of APC in septic patients might be due, in part, to improved intestinal microcirculation.
严重脓毒症和脓毒性休克的成功治疗仍然是重症医学中的一项重大挑战。最近引入的重组人活化蛋白C(APC)显著改善了脓毒症患者的预后。APC对肠道循环的影响仍知之甚少。因此,本研究旨在通过活体显微镜观察,研究APC对大鼠实验性内毒素血症期间肠道微循环的影响。
总共44只雄性Lewis大鼠被随机分配,分别接受静脉注射15mg/kg单独的脂多糖(LPS)(n = 11)或LPS后再注射2mg/kg重组人APC(LPS + APC)(n = 11),而对照组动物接受APC(n = 11)或生理盐水(n = 11)。通过活体荧光显微镜观察动物肠壁微循环中功能性毛细血管密度和白细胞在小静脉内皮上的黏附情况。测量体循环指标以及肿瘤坏死因子-α、白细胞介素(IL)-1β、IL-6和IL-10的血浆水平。
尽管对接受LPS治疗的大鼠和对照大鼠给予APC均未改变体循环或炎性细胞因子的释放,但与未接受APC的LPS治疗动物相比,LPS + APC治疗的动物黏膜和肌肉功能性毛细血管密度增加(分别为p < 0.001和p < 0.05),肠黏膜下层V1和V3小静脉中牢固黏附的白细胞数量减少(p < 0.01)。两个对照组之间未观察到可归因于APC治疗的显著差异。
实验性内毒素血症期间给予APC可通过保护功能性毛细血管密度(作为微血管灌注的指标)改善肠道微循环,并通过减少白细胞在黏膜下小静脉内皮上的黏附发挥抗炎作用。因此,APC对脓毒症患者的有益作用可能部分归因于肠道微循环的改善。